Markets

Amgen (AMGN) Reports Encouraging Top-Line Data on AMG 416 - Analyst Blog

Amgen Inc. ( AMGN ) announced that AMG 416 has met the primary as well as secondary endpoints in the second phase III registration study evaluating the candidate for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease (CKD), receiving hemodialysis. We expect investors to react positively to the news.

Data from the 26-week, randomized, double-blind, placebo-controlled study revealed that a statistically significant number of patients on AMG 416 achieved greater than 30% reduction in parathyroid hormone levels compared to patients on placebo (74% versus 8.3%).

In Jul 2014, the company had announced positive data from another phase III study evaluating the efficacy and safety of AMG 416 in CKD patients receiving hemodialysis and suffering from secondary hyperparathyroidism. The study met all its primary and secondary endpoints.

Amgen is also conducting a head-to-head study evaluating AMG 416 in comparison with Sensipar (cinacalcet). Results should be out in 2015. We remind investors that the acquisition of KAI Pharmaceuticals, Inc. in Jul 2012 added AMG 416 to Amgen's pipeline.

Secondary hyperparathyroidism is often progressive in patients suffering from CKD. According to the press release issued by Amgen, secondary hyperparathyroidism affects a large number of the approximately two million dialysis-dependent patients worldwide.

Amgen carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the biotech sector include Gilead Sciences Inc. ( GILD ), Alexion Pharmaceuticals, Inc. ( ALXN ) and Medivation, Inc. ( MDVN ). While Gilead carries a Zacks Rank #1 (Strong Buy), Alexion and Medivation are Zacks Rank #2 (Buy) stocks.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

AMGEN INC (AMGN): Free Stock Analysis Report

ALEXION PHARMA (ALXN): Free Stock Analysis Report

GILEAD SCIENCES (GILD): Free Stock Analysis Report

MEDIVATION INC (MDVN): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

GILD ALXN AMGN

Other Topics

Stocks

Latest Markets Videos

    Zacks

    Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at www.zacks.com.

    Learn More